

Author Index Volume 1

Aliot E, 669
Amerini S, 101
Amodeo C, 359
Angioni L, 535
Antman EM, 183
Arnold JMO, 183

Barlow JW, 543
Bauer JH, 349
Ben-David A, 523
Bender F, 367
Bernstein V, 661
Binetti G, 161
Bleifeld W, 177
Blumlein S, 65
Bolognesi R, 353
Bonandi L, 513
Boselli L, 535
Branzi A, 161
Burnett JC Jr, 89

Camm AJ, 599
Castiglioni G, 535
Cavalcabo P de B, 101
Cerbai E, 101
Chatterjee K, 1
Chiu AT, 377
Clark RE, 687
Clusin WT, 335
Coetzee WA, 447
Cohen D, 523
Cohn JN, 191
Commerford RJ, 671
Courtney KR, 117
Cucchini F, 353
Cumming AMM, 45
Cuspidi C, 535

Dei Cas L, 513
Digitalis Subcommittee, 125

Ebner FX, 403
Edwards BS, 89
Elharrar V, 133
Eliahou HE, 523
Enjalbert M, 661
Euler DE, 605

Faucon G, 559

Feroldi P, 513
Ferrans VJ, 687
Ferrera LA, 657
Ferrari R, 353
Ferretti RM, 161
Friedman PL, 183
Frohlich ED, 345
Frohlich ED, 359
Furberg CD, 343

Garrett J, 65
Gavendo S, 523
Gilgenkrantz JM, 669
Giovannelli N, 161
Good AP, 529
Goodwin JF, 665
Gottlieb C, 155
Gulker H, 367
Guth BD, 503

Haverkamp W, 367
Hearse DJ, 133
Hecker H, 71
Hellberg B, 523
Herman EH, 687
Herzog D, 523
Higgins CB, 493
Hindricks G, 367
Hori M, 169

Inoue M, 169
Isshiki T, 359

James TL, 493
Jett GK, 687
Jones M, 687
Josephson ME, 155
Jost S, 71

Kapuler S, 523
Kawai C, 169
Khurmi NS, 81
Knorr A, 393
Kodama K, 169
Kogan N, 523
Krebs R, 613
Kusukawa R, 169

Lakhal M, 559

Lang J, 559
Leary WP, 29
Lefer AM, 385
Lehtonen A, 549
Leier CV, 529
Lessem JN, 441
Lichtlen PR, 71

Magnani B, 161
Mancia G, 535
Mancini M, 657
Manning AS, 133
Marie PY, 669
Markiewicz W, 493
Marotta T, 657
Mastranzo P, 657
Mehta D, 599
Meredith Pa, 45
Messerli FH, 359
Metra M, 513
Miller CR, 377
Morgan JP, 621
Morton JJ, 45
Mugelli A, 101

Nakamura M, 169
Nakaya Y, 133
Natoff IL, 15
Nayler WG, 617
Negroni S, 161
Nellessen U, 71
Neufeld HN, 403
Nodari S, 513
Nonogi H, 169
Non YP, 559
Nordio G, 513

Opie IH, 1
Opie IH, 57
Opie IH, 109
Opie IH, 111
Opie IH, 195
Opie IH, 411
Opie IH, 461
Opie IH, 625
Ophof T, 573
Osborne JA, 385
Pancaldi S, 161

Parker JO, 661
Parmley WW, 65
Parmley WW, 493
Pasanisi F, 657
Pegram BL, 359
Pocock WA, 543

Raddino R, 513
Rafflenbeul S, 71
Rafferty EB, 81
Rashid T, 65
Reicher-Reiss H, 403
Renaud JF, 677
Reyes AJ, 29
Ribout C, 51
Riva E, 133
Rochette L, 51
Ross J Jr, 503

Sakurai T, 169
Sampieri L, 535
Sasayama S, 169
Scanlon RJ, 605
Schofer J, 177
Schwartz A, 439
Semple PF, 45
Serban I, 523
Sievers R, 493
Sievers RE, 65
Smith TW, 183
Specchia S, 161
Sugimoto T, 169
Sun J-Z, 385
Surawicz B, 133
Swartz SL, 39

Takishima T, 169
Thaulow E, 503
Thoolen MUMC, 377
Timmermans PEMM, 377
Timour Q, 559
Trechot P, 669
Trillet V, 559

Unverferth DV, 529

Visentin S, 101
Visioli O, 353
Visioli O, 513

Ward DE, 599
Watters TA, 493
Weinberger MH, 9
Wenger NK, 553
Wikman-Coffelt J, 493
Wu SS, 493

Yanagisawa A, 385
Yasuda H, 169
Yusuf S, 343

Zanchetti A, 535
Zannad F, 669
Zimmerman RS, 89

Subject Index

Volume 1

- acetylcholine
 - atherosclerosis and, 385
 - vascular smooth muscle and, 385
 - vascular responsiveness and, 385
- acidosis
 - ionic transporters and, 677
 - metabolic, 493
 - trimetazidine and, 677
 - verapamil and, 493
- action potentials
 - antiarrhythmic drug design and, 117
- activation pattern
 - mammalian sinoatrial node and, 573
- acute myocardial infarction
 - calcium antagonists and, 461
- adenosine diphosphate
 - vascular responsiveness and, 385
- α_1 -receptor
 - blood pressure and, 377
 - calcium antagonists and, 377
 - congestive heart failure, 529
 - hypertensive rats and, 377
 - vasoconstrictor response and, 377
- α -adrenergic blockade
 - heart failure and, 529
- α -adrenoceptors
 - hypertension and, 537
- amiodarone
 - action potential duration and, 141
 - canine cardiac fibers, and 141
 - hypertrophic cardiomyopathy and, 665
- angina at rest
 - calcium antagonists and, 461
 - definition, 461

angina pectoris

- calcium antagonists and, 81, 461, 513, 661

- combined with hypertension, 513

- angina unstable, 461, 671

angiotensin

- congestive heart failure and, 1

angiotensin converting enzyme

(ACE) inhibitors

- comparison of captopril and, 45
- comparison of enalaprilic and, 45
- comparison of lisinopril and, 45
- congestive heart failure in, 1
- hypertension in, 9, 111
- ischemic heart disease, 111
- prostaglandins and, 39
- rate of onset of action, 45
- recent advances, 111
- urate renal excretion and, 29
- ventricular fibrillation and, 51

anthracycline antibiotics

- cardiac toxicity and, 559

- anti-ischemic action of nisoldipine, 393

antiarrhythmic

- drug design, 117
- effect of superoxide dismutase, 133
- drugs and digoxin, interaction, 183
- effects of ACE inhibitors, 51
- effects of propranolol, 605
- mechanisms, 117

antiatherosclerotic therapy

- INTACT trial, 71

antihypertensive action

- diltiazem of, 359
- nisoldipine of, 393
- renal function and, 359

aortic rings

- atherosclerosis and, 385

arrhythmias

- action potentials and, 117
- antiarrhythmic drug action and, 141
- drug design and, 117
- hypertrophic cardiomyopathy and, 665

arteritis

- minoxidil and, 687

atenolol

- compared with pindolol, 549

atherosclerosis

- animal models, 65
- coronary atherosclerosis, clinical presentation, 671
- drug trials, 71

atrial lesions

- minoxidil and, 687

atrial natriuretic factor

- aldosterone and, 89
- heart failure and, 89

baroreflexes

- calcium antagonists and, 625

beta-adrenergic blockade

- membrane effects, 605

beta-blockers

- hypertrophic cardiomyopathy and, 665

beta₂-agonists

- albuterol and, 101

binding sites

- calcium antagonists and, 411

blood lipids

- blood cholesterol and β -blockers, 549

blood pressure

- homeostasis, 535
- renin and, 9
- see also hypertension

bradykinin

- captopril and, 9

calcium

- calcium antagonists and, 411, 613
- congestive heart failure and, 621

calcium antagonists

- angina pectoris and, 81, 461, 661
- arrhythmias and, 335, 367, 625
- atherosclerosis and, 71
- blood pressure and, 377
- calcium current and, 447
- cardiomyopathy and, 625
- classification, 411
- coronary artery disease and, 71
- future uses, 613
- hyperfiltration and, 359
- hypertension and, 359, 377, 625
- internal (site of action), 621
- ischemia, myocardial and, 367, 503
- ischemic heart disease and, 461
- myocardial infarction and, 343
- post-infarction and, 343, 617
- renal failure and, 349
- renal vasodilation and, 359
- sudden cardiac death and, 335
- supraventricular arrhythmias and, 625
- unstable angina and, 461
- whither now, 617

calcium blockers

- see calcium antagonists

calcium channel blockers

- see calcium antagonists

calcium entry blockers

- see calcium antagonists

calcium ion antagonists

- see calcium antagonists

calcium overload

- congestive heart failure and, 621

captopril

- congestive heart failure and, 111, 177
- dilated cardiomyopathy and, 177
- hypertension and, 9, 29
- gout and, 29
- onset of action, 45
- quality of life, 557
- prostaglandins and, 39
- urate excretion and, 29

cardiac

- cardiac arrest, 155
- cells, 677
- contractility, 353
- electrophysiology, 605
- glycosides, 125
- hemodynamics, 353
- metabolism, 493

cardiomyopathy

- calcium antagonists and, 625
- dilated, 177
- hypertrophic, 665
- idiopathic dilated, 403

cardiotoxicity of doxorubicin, 559

central nervous effects

- calcium antagonists of, 613

chlorthalidone

- hypertension and, 657
- with nifedipine, 657

cholesterol

- atenolol and, 549
- calcium antagonists and, 65, 71
- pindolol and, 549
- vascular responsiveness and, 387
- verapamil and, 65

chronic stable angina

- see angina pectoris

clonidine

- congestive heart failure and, 529

collagen content isolated nodal tissue, 573

- congestive heart failure
 - ACE inhibitors and, 1,9, 553
 - alpha-adrenergic blockade and, 527
 - arrhythmias and, 195
 - atrial natriuretic factor and, 89
 - beta₂-stimulation and, 101
 - calcium and, 621
 - calcium antagonists and, 625
 - captopril and, 9
 - clonidine and, 529
 - digitalis and, 195
 - diuretics and, 13, 195
 - felodipine and, 161
 - heart and, 191
 - hydralazine and, 177
 - indoramin and, 529
 - inotropic agents and, 169
 - non-steroidal anti-inflammatories and, 109
 - OPC-8212 and, 169
 - quality of life and, 553
 - peripheral circulation and, 191
 - potassium and, 195
 - sympathetic activity and, 177
 - vasodilators and, 1, 161
- contractility
 - cardiac beta₂-adrenoceptors and, 101
- converting enzyme inhibitors
 - see ACE inhibitors
- coronary arteries
 - atherosclerosis and, 385
 - prostacyclin and, 385
- coronary artery disease
 - acute myocardial infarction and, 671
 - calcium antagonists and, 71
 - sudden death and, 671
 - unstable angina and, 671
- counter-regulation
 - calcium antagonists and, 625
- digitalis
 - arrhythmias and, 195
 - calcium antagonists and, 441
- digoxin
 - antiarrhythmic agents and, 183
 - calcium antagonists and, 183, 441
 - pharmacokinetic interactions and, 183
- dilated cardiomyopathy
 - sympathetic activity and, 177
- diltiazem
 - angina pectoris and, 81, 461
 - binding site and, 411
 - chronic stable angina and, 81, 461
 - digitalis and, 441
 - exercise-induced ischemia and, 503
 - hyperfiltration and, 359
 - hypertension and, 345, 359, 625
 - ischemia and, 503
 - ischemic heart disease and, 461
 - renal function and, 345, 359
 - silent ischemia and, 461
 - site of action and, 411
 - supraventricular arrhythmias and, 625
- disopyramide
 - excitability and, 141
 - refractoriness and, 141
 - hypertrophic cardiomyopathy and, 665
- diuretics
 - ACE inhibitors and, 9
 - arrhythmias and, 195
 - urate excretion and, 29
- doxorubicin
 - myocardial damage and, 559
- drug interactions
 - antiarrhythmic agents and, 183
 - calcium antagonists and, 183, 441
 - digoxin and, 183
- effort angina
 - calcium antagonists and, 81, 461

- electrophysiology
 - flecainide of, 599
- enalapril
 - congestive heart failure in, 111
 - hepatitis and, 669
 - onset of action, 45
 - prostaglandins and, 39
 - urate excretion and, 29
- enalaprilic acid
 - onset of action, 45
- endothelium
 - atherosclerosis and, 385
- exercise testing
 - calcium antagonists and, 81
 - isradipine and, 661
- exercise-induced ischemia
 - diltiazem and, 503
- felodipine
 - congestive heart failure and, 161
- flecainide acetate
 - electrophysiological testing and, 599
 - paroxysmal tachycardia and, 599
- free radicals
 - arrhythmias and, 133
 - regional ischemia and, 133
 - reperfusion and, 133
- gallopamil
 - compared with nifedipine, 367
 - ischemic arrhythmias and, 367
 - reperfusion arrhythmias and, 367
 - ventricular fibrillation and, 367
- glomerular filtration
 - diltiazem and, 359
 - nisoldipine and, 523
- glucose
 - β -blockers and, 549
- gout
 - ACE inhibitors and, 29
- heart failure, see congestive heart failure
- hemodynamics
 - minoxidil and, 687
- hepatitis
 - ACE inhibitors and, 669
- hydralazine
 - dilated cardiomyopathy and, 177
- hypertension
 - ACE inhibitors and, 9
 - α_1 -adrenergic blockade, 535
 - atenolol and, 549
 - calcium antagonists and, 617, 625, 657
 - diltiazem and, 345
 - diuretics and, 657
 - lipid changes and, 549
 - nifedipine and, 657
 - non-steroidal anti-inflammatories and, 109
 - pindolol and, 549
 - renal mechanisms and, 349
 - trimazosin and, 535
- hypertrophic cardiomyopathy,
 - pharmacological therapy of, 665
- hyperuricaemia
 - ACE inhibitors and, 29
- indoramin
 - congestive heart failure and, 529
 - INTACT Study, 71
- internal calcium
 - heart failure and, 621
- intrarenal hemodynamics
 - diltiazem and, 359
 - hypertension and, 359
- ionic transporters
 - acidosis and, 677
 - trimetazidine and 677
- ischemia
 - calcium antagonists and, 367, 461, 503
 - calcium current and, 447
 - nisoldipine and, 393
 - regional, and arrhythmias, 133

- ischemic heart disease
 - β -blockade and, 533
 - calcium antagonists and, 461, 613
 - nifedipine and, 533
 - see also angina pectoris
- isradipine
 - angina pectoris and, 661
- kidneys
 - renal function and nisoldipine, 523
- kinetics
 - antiarrhythmic drug action and, 141
 - calcium channels of, 447
 - V_{\max} block of, 141
- L- and T-type calcium channels, 447
- lipid solubility
 - antiarrhythmic drugs of, 117
- lisinopril
 - onset of action, 45
- methyl dopa
 - quality of life and, 553
- mexiletine, 141
- migraine, 625
- mild hypertension, 553
- minoxidil
 - atrial lesions and, 687
- mitochondria
 - verapamil and, 493
- mixed angina
 - calcium antagonists and, 461
- monophasic action potential
 - flecainide and, 599
- morphological reconstruction
 - sinoatrial node of, 573
- myocardial blood flow - regional
 - influence of minoxidil, 687
- myocardial infarction
 - calcium antagonists and, 343
- myocardial ischemia
 - calcium antagonists and, 503, 617
- myocardial necrosis
 - minoxidil and, 687
- neurotransmitters
 - calcium current and, 447
- nicardipine
 - angina pectoris and, 513
 - nifedipine and, 513
- nifedipine
 - acute myocardial infarction and, 461
 - α_1 -receptors and, 377
 - angina pectoris and, 81, 513, 461
 - atherosclerosis and, 71
 - β -blockade and, 353
 - binding sites and, 411
 - chlorthalidone and, 657
 - contractility and, 353
 - coronary artery disease and, 353
 - digitalis and, 441
 - diltiazem and, 81
 - exercise and, 503
 - gallopamil and, 367
 - hemodynamics and, 353
 - hypertension and, 377, 513, 625, 657
 - INTACT trial and, 71
 - ischemic heart disease and, 461, 503
 - mixed angina and, 461
 - nisoldipine and, 393
 - silent ischemia and, 461
 - unstable angina and, 461
- nisoldipine
 - antihypertensive effect of, 393
 - anti-ischemic effect of, 393
 - chronic renal failure and, 523
 - pharmacology of, 393
- nitroglycerin
 - vasodilation and, 385
- nodal tissue
 - mammalian sinoatrial node and, 573

- non-sustained ventricular tachycardia
 - programmed electrical stimulation and, 157
- norepinephrine
 - dilated cardiomyopathy and, 177
- nuclear magnetic resonance
 - verapamil and, 493
- OPC-8212
 - congestive heart failure and, 169
- PG E_2 -metabolites
 - hypertension and, 39
- pH
 - trimetazidine and, 677
- pacemaker shift
 - sinoatrial node and, 573
- paroxysmal tachycardia
 - flecainide and, 599
- pathogenesis
 - coronary artery disease of, 671
- perindopril, 51
- pharmacokinetics
 - digoxin of, 183
- pindolol
 - blood cholesterol and, 549
- piperanometozine
 - congestive heart failure and, 169
- plasma renin activity
 - chlorthalidone and, 657
 - nifedipine and, 657
- positive inotropic agent
 - congestive heart failure and, 169
- post-infarction
 - calcium antagonists and, 343, 617
 - cardiac glycosides and, 125
 - digitalis and, 125
- post-repolarization refractoriness
 - antiarrhythmic drug classification and, 141
- potassium
 - arrhythmias and, 195
 - congestive heart failure and, 195
- prazosin
 - congestive heart failure and, 529
- premature impulse
 - amiodarone and, 141
 - disopyramide and, 141
 - mexiletine and, 141
- proarrhythmic
 - effects of antiarrhythmic drugs, 117
- programmed electrical stimulation
 - ventricular arrhythmias and, 157
- prophylaxis, post-infarct, 343, 617
- propranolol
 - ventricular repolarization and, 605
- prostacyclin
 - vascular responsiveness and, 385
- prostaglandins
 - ACE inhibitors, 39
 - atherosclerosis and, 385
- Purkinje fiber automaticity
 - tulobuterol and, 101
- quality of life
 - hypertension and, 553
- Raynaud's phenomenon
 - calcium antagonists and, 625
- regional ischemia
 - reperfusion-induced arrhythmias and, 133
 - superoxide dismutase and, 133
- regional myocardial blood flow
 - minoxidil and, 687
- renal failure
 - calcium antagonists and, 349
 - chronic and nisoldipine, 523
 - function and ACE inhibitors, 1
 - function and vasodilators, 1
 - function and diltiazem, 345
 - function and hemodynamics, 359
 - intrarenal hemodynamics, 359
- renin
 - angiotensin-converting enzymes, 1

- reperfusion
 - ACE inhibitors and, 51
 - arrhythmias and, 133
 - calcium antagonists and, 367
 - captopril and, 51
 - enalapril and, 51
 - gallopamil and, 367
 - nifedipine and, 367
 - perindopril and, 51
 - superoxide dismutase and, 133
- selectivity
 - calcium current and, 447
- silent ischemia
 - calcium antagonists and, 461
- sinoatrial node
 - morphology and, 573
- sinoatrial node dysfunction
 - pacemaker shift and, 573
- sinus node
 - see sinoatrial node, 573
 - tulobuterol and, 101
- sodium channels
 - antiarrhythmic drugs and, 117
- spectroscopy
 - acidosis and, 493
 - verapamil and, 493
- spontaneously hypertensive rats
 - α_1 -adrenergic blockers and, 377
 - calcium antagonists and, 377
- strength-interval curve
 - amiodarone and, 141
 - disopyramide and, 141
 - mexiletine and, 141
- sudden cardiac death
 - calcium modulation and, 335
- superoxide dismutase
 - reperfusion arrhythmias and, 133
- supraventricular arrhythmias
 - calcium antagonists and, 625
- sustained uniform ventricular tachycardia
 - programmed electrical stimulation and, 155
- sympathetic activity
 - captopril and, 177
 - hydralazine and, 177
 - idiopathic dilated cardiomyopathy and, 177
 - propranolol and, 605
 - ventricular arrhythmias and, 605
- syncope
 - programmed electrical stimulation and, 157
- systemic hemodynamics
 - diltiazem and, 359
- systemic hypertension
 - diltiazem and, 159
 - nicardipine and, 513
- thrombosis
 - coronary artery disease and, 671
- thromboxane A_2 , 385
- tiapamil
 - angina pectoris and, 81
 - hypertension and, 377
- trimazosin
 - hypertension and, 535
- trimetazidine
 - acidosis and, 535
- unstable angina
 - calcium antagonists and, 461
- uricosuria
 - ACE inhibitors and, 29
 - captopril and, 29
 - enalapril and, 29
- urinary electrolytes
 - chlorthalidone and, 657
 - nifedipine and, 657
- vascular smooth muscle
 - atherosclerosis and, 385
 - prostaglandins and, 385
- vascular tone
 - ACE inhibitors and, 1

vasoconstrictor responses

- alpha₁-adrenoceptor stimulation and, 377
- spontaneously hypertensive rats and, 377

vasodilators

- alpha₁-adrenergic blockers and, 535
- calcium antagonists and, 411
- congestive heart failure and, 1, 529
- hypertension and, 535
- minoxidil and, 687

ventricular arrhythmias

- calcium antagonists and, 335, 367
- digitalis and, 125
- flecainide and, 599
- gallopamil and, 367
- nifedipine and, 367
- programmed electrical stimulation and, 155
- propranolol and, 605

ventricular refractory period

- propranolol and, 605

verapamil

- acidosis and, 493
- alpha₁-adrenoceptor stimulation, 377
- angina and, 81, 461
- arrhythmias and, 625
- atherosclerosis and, 65
- binding sites and, 41
- blood pressure and, 377, 625
- digitalis and, 441
- exercise-induced ischemia, 503
- hypertension and, 625
- hypertrophic cardiomyopathy and, 665
- supraventricular arrhythmias and, 625

